CHARLEROI, Belgium--(BUSINESS WIRE)--Delphi Genetics SA (“Delphi”) today announced that the company has entered into an agreement with Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, for the manufacture of biological pharmaceuticals using Delphi’s patented StabyExpressTM technology.
